Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 20/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30172963 | 0.95 | USP1 (0.44) | USP1 | |
| SCHEMBL25978836 | 0.90 | HDAC1 (0.42) | USP1 | |
| SCHEMBL25978832 | 0.90 | USP1 (0.37) | USP1 | |
| SCHEMBL30509284 | 0.89 | USP1 (0.46) | USP1 | |
| SCHEMBL29036296 | 0.89 | USP1 (0.46) | USP1 | |
| SCHEMBL25978956 | 0.88 | USP1 (0.43) | USP1 | |
| SCHEMBL25978955 | 0.88 | USP1 (0.43) | USP1 | |
| SCHEMBL25978838 | 0.86 | USP1 (0.38) | USP1 | |
| SCHEMBL25978953 | 0.85 | USP1 (0.42) | USP1 | |
| SCHEMBL27174536 | 0.84 | USP1 (0.42) | USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4547336-A1 | USP1 INHIBITORS AND USES THEREOF | Zentaur Therapeutics USA Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119836421-A | USP1 inhibitors and uses thereof | 森韬医药美国公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4472946-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | Exelixis, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | FORMA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | FORMA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | FORMA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. | 2024-03-21 | — | — | US | disclosed |
| EP-4319758-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | Forma Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4321515-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | Simcere Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| WO-2024006879-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-117241801-A | Inhibition of ubiquitin-specific protease 1 (USP 1) | 福马治疗有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117136189-A | Ubiquitin-specific protease 1 (USP 1) inhibitors | 先声再明医药有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| WO-2022216820-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | FORMA THERAPEUTICS, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | USP1, USP2, USP3 | USP1 1/4885 |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | USP1, USP28, USP2 | USP1 1/4885 |
| US-20240239808-A1 | INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) | USP1, USP2, USP3 | USP1 1/4885 |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | USP1, USP2, SUMO1 | USP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.